Actinic Keratosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Analysis of Clinical Trials, Therapies, MOA, ROA, and Developments | Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Actinic Keratosis pipeline constitutes 10+ key companies continuously working towards developing 10+ Actinic Keratosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Actinic Keratosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Actinic Keratosis Market.

The Actinic Keratosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Actinic Keratosis Pipeline Report: https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Actinic Keratosis treatment therapies with a considerable amount of success over the years.
• Actinic Keratosis companies working in the treatment market are Bausch Health Companies, Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma, DFB Soria, LLC, Coegin Pharma AB, and others, are developing therapies for the Actinic Keratosis treatment
• Emerging Actinic Keratosis therapies in the different phases of clinical trials are- ALDARA (imiquimod), SOLARAZE (diclofenac topical gel), KLISYRI (tirbanibulin/KX01/ KX2-391), VDA-1102, SR-T100 Gel, Tuvatexib (VDA-1102), SOR-007, AVX-001, and others are expected to have a significant impact on the Actinic Keratosis market in the coming years.
• In November 2024, Vidac Pharma has raised an additional €600,000 ($645,651) in funding to further the clinical development of its two leading cancer drug candidates. This funding, secured from existing investors and announced during the company's recent shareholder meeting, will enable Vidac to launch a new Phase IIb trial for its lead drug, VDA-1102 (tuvatexib) ointment. The hexokinase 2 inhibitor is being evaluated for its potential in treating advanced actinic keratosis, a skin condition that can develop into cutaneous squamous cell carcinoma (SCC).
• In October 2024, Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on dermatologic product commercialization, announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) to increase the maximum approved dosage of Ameluz® from one to three tubes per treatment. This approval enables the larger field treatment of actinic keratosis (AK) on the face and scalp using Ameluz®-PDT with either the BF-RhodoLED or RhodoLED XL lamp.

Actinic Keratosis Overview
Actinic keratosis (AK), also known as solar keratosis, is a pre-cancerous condition that develops on skin exposed to the sun. It appears as rough, scaly patches or spots, often red or brown, typically on sun-damaged areas like the face, ears, neck, scalp, chest, backs of hands, arms, or lips. AK is caused by prolonged ultraviolet (UV) light exposure, leading to abnormal growth of skin cells. While most AKs are not cancerous, they can develop into squamous cell carcinoma if left untreated. Treatment options include topical therapies, cryotherapy, laser treatment, and sometimes surgical removal.

Get a Free Sample PDF Report to know more about Actinic Keratosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Actinic Keratosis Drugs Under Different Phases of Clinical Development Include:
• ALDARA (imiquimod): Bausch Health Companies
• SOLARAZE (diclofenac topical gel): Sandoz Pharmaceuticals
• KLISYRI (tirbanibulin/KX01/ KX2-391): Athenex/ Almirall
• VDA-1102: Vidac Pharma
• SR-T100 Gel: G&E Herbal Biotechnology
• Tuvatexib (VDA-1102): Vidac Pharma
• SOR-007: DFB Soria, LLC
• AVX-001: Coegin Pharma AB

Actinic Keratosis Route of Administration
Actinic Keratosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Actinic Keratosis Molecule Type
Actinic Keratosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Actinic Keratosis Pipeline Therapeutics Assessment
• Actinic Keratosis Assessment by Product Type
• Actinic Keratosis By Stage and Product Type
• Actinic Keratosis Assessment by Route of Administration
• Actinic Keratosis By Stage and Route of Administration
• Actinic Keratosis Assessment by Molecule Type
• Actinic Keratosis by Stage and Molecule Type

DelveInsight's Actinic Keratosis Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Actinic Keratosis product details are provided in the report. Download the Actinic Keratosis pipeline report to learn more about the emerging Actinic Keratosis therapies at:
https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Actinic Keratosis Therapeutics Market include:
Key companies developing therapies for Actinic Keratosis are - VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, DermAct Pharmaceutical, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma Corporation, and others.

Actinic Keratosis Pipeline Analysis:
The Actinic Keratosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Actinic Keratosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Actinic Keratosis Treatment.
• Actinic Keratosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Actinic Keratosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Actinic Keratosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Actinic Keratosis drugs and therapies- https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Actinic Keratosis Pipeline Market Drivers
• Increasing Prevalence of Sun Exposure, Rising Awareness, Advances in Topical Therapies, Growing Focus on Skin Cancer Prevention, Regulatory Approvals, Aging Population, are some of the important factors that are fueling the Actinic Keratosis Market.

Actinic Keratosis Pipeline Market Barriers
• However, High Treatment Costs, Side Effects of Current Treatments, Limited Awareness in Low-Resource Regions, Stigma Around Dermatological Treatments, Regulatory Challenges, Competition from Established Therapies, and other factors are creating obstacles in the Actinic Keratosis Market growth.

Scope of Actinic Keratosis Pipeline Drug Insight
• Coverage: Global
• Key Actinic Keratosis Companies: Bausch Health Companies, Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma, DFB Soria, LLC, Coegin Pharma AB, and others
• Key Actinic Keratosis Therapies: ALDARA (imiquimod), SOLARAZE (diclofenac topical gel), KLISYRI (tirbanibulin/KX01/ KX2-391), VDA-1102, SR-T100 Gel, Tuvatexib (VDA-1102), SOR-007, AVX-001, and others
• Actinic Keratosis Therapeutic Assessment: Actinic Keratosis current marketed and Actinic Keratosis emerging therapies
• Actinic Keratosis Market Dynamics: Actinic Keratosis market drivers and Actinic Keratosis market barriers

Request for Sample PDF Report for Actinic Keratosis Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Actinic Keratosis Report Introduction
2. Actinic Keratosis Executive Summary
3. Actinic Keratosis Overview
4. Actinic Keratosis- Analytical Perspective In-depth Commercial Assessment
5. Actinic Keratosis Pipeline Therapeutics
6. Actinic Keratosis Late Stage Products (Phase II/III)
7. Actinic Keratosis Mid Stage Products (Phase II)
8. Actinic Keratosis Early Stage Products (Phase I)
9. Actinic Keratosis Preclinical Stage Products
10. Actinic Keratosis Therapeutics Assessment
11. Actinic Keratosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Actinic Keratosis Key Companies
14. Actinic Keratosis Key Products
15. Actinic Keratosis Unmet Needs
16 . Actinic Keratosis Market Drivers and Barriers
17. Actinic Keratosis Future Perspectives and Conclusion
18. Actinic Keratosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Actinic Keratosis Market https://www.delveinsight.com/report-store/actinic-keratosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Actinic Keratosis Epidemiology https://www.delveinsight.com/report-store/actinic-keratosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Actinic Keratosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.